• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    11.10 -0.16 (-1.42%)
    Streaming Delayed Price Updated: 12:31 PM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    TLX101-Px (Pixlumi®) MAA Accepted in Europe
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts NDA for TLX101-Px (Pixclara®)
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Appoints David Gill as Non-Executive Director
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Investor Education Webinar
    The Future of Prostate Imaging: What do physicians want? 
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Participate in Oppenheimer and TD Cowen Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Full Year Results 2025 Investor Webcast Notification
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FRIDAY DEADLINE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
    From Berger Montague
    Via GlobeNewswire
    News headline image
    TLX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.